Abstract :
Background: Effective therapeutic therapy of blood culture positives requires early identification of medication resistance. By lowering mortality and morbidity, it improves patient outcomes, permits prompt and focused antibiotic therapy, and slows the spread of resistant infections. Early detection can also aid in the prevention of inefficient therapies, which can result in more economical healthcare costs and more effective use of resources. For all intents and purposes, it is essential in mitigating the impact of drug-resistant illnesses.Materials and Methods: To determine whether 100 positive blood cultures produced carbapenemase, the bcCIM test was used. All Gram-negative bacilli (GNB) were subjected to the mCIM test and subcultures of positive blood cultures. The outcomes were contrasted with each isolate's VITEK MIC results.Results: Klebsiella pneumoniae was the most common isolate (55/100, 55%), followed by Escherichia coli (41/100, 41%), Enterobacter cloacae (3/100, 3%), and Proteus mirabilis (1/100, 1%). 47 isolates have carbapenemase production identified by mCIM. In comparison with mCIM, bcCIM demonstrated 92% overall accuracy, 100% specificity (53/53; 95% CI 93.3–100), and sensitivity 82.98% (39/47; 95% CI 69.2–91.6). Strong consistency was indicated by the bcCIM and mCIM's 0.838 kappa agreement.Conclusion: Rapid pathogen identification with susceptibility profiling is necessary for sepsis caused by multidrug-resistant gram-negative pathogens. In order to improve infection management and targeted medication, this study suggests standardizing the blood culture carbapenem inactivation method (bc-CIM) for faster and more economical carbapenemase detection. When positive blood cultures are subjected to Direct Susceptibility Testing (DST), turnaround times are considerably reduced, which improves results by enabling quicker, more appropriate treatment.
Keyword :
Drug resistance, Blood cultures, Carbapenem inactivation method, bc-CIM.